Machine learning (ML) prediction of anemia in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) treated with talazoparib (TALA) + enzalutamide (ENZA)

Category Primary study
ConferenceEuropean Society For Medical Oncology Congress, ESMO 2025
Year 2025
This article has no abstract
Epistemonikos ID: af8c4e7fa4d04f444b33d9580521ae728d992aa9
First added on: May 16, 2026